
Ann Rheum Dis: first published as on 1 December 2009. Downloaded from http://ard.bmj.com/ on September 25, 2020 by





Cover image: FOXP3+ cells in synovial tissue from two patients with rheumatoid arthritis. See p1913

Editor

Tore K Kvien

Associate Editors

Francis Berenbaum Hans Bijlsma **Dimitrios Boumpas** Gerd Burmester Mary Crow lain McInnes

Editorial office

Annals of the Rheumatic Diseases BMJ Publishing Group Ltd **BMA** House

Tavistock Square London WCIH 9JR, UK

T: +44 (0)20 7383 6250

F: +44 (0)20 7383 6668

E: ard@bmj.com

ISSN: 0003-4967 (print) ISSN: 1468-2060 (online) **Impact Factor:** 7.188

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2009 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Mercury International Ltd. Periodicals postage paid at Rahway, NJ, USA. POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Mercury International Ltd, 365 Blair Road, Avenel, NJ 07001, USA.

Editorial

Contents

1797 Quality indicators in rheumatology: valid for whom?

T P M Vliet Vlieland, T W I Huizinga

Viewpoint

1800 Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases


> V Strand, B Crawford, J Singh, E Choy, J S Smolen, D Khanna

Clinical and epidemiological research

- 1805 Development of quality indicators for monitoring of the disease course in rheumatoid arthritis LTC van Hulst, I Fransen, AA den Broeder, RGrol. PLCM van Riel, MEIL Hulscher
- 1811 ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis

D van der Heijde, E Lie, T K Kvien, J Sieper, F Van den Bosch, J Listing, J Braun, R Landewé, for the Assessment of SpondyloArthritis international Society (ASAS)

1819 Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment



1827 Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

C Mukhtyar, R Lee, D Brown, D Carruthers, B Dasgupta, S Dubey, O Flossmann, C Hall, I Hollywood, D Jayne, R Jones, P Lanyon, A Muir, D Scott, L Young, R A Luqmani

1833 Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-

> IN Hoes, IWG Jacobs, SMM Verstappen, I W I Bijlsma, G I M G Van der Heijden

1839 Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study

D Vosse, R Landewé, D van der Heijde, S van der Linden, T-P van Staa, P Geusens

1843 Efficacy and safety of steroid injections for shoulder and elbow tendonitis: a meta-analysis of randomised controlled trials

C Gaujoux-Viala, M Dougados, L Gossec

1850 Reliability of high-resolution ultrasonography in the assessment of Achilles tendon enthesopathy in seronegative spondyloarthropathies

> E Filippucci, S Zehra Aydin, O Karadag, F Salaffi, M Gutierrez, H Direskeneli, W Grassi

1856 Comparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomide

> A Strangfeld, F Hierse, J Kekow, U von Hinueber, H-P Tony, R Dockhorn, J Listing, A Zink

1863 Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

> G R Burmester, P Mease, B A C Dijkmans, K Gordon, D Lovell, R Panaccione, J Perez, A L Pangan

1870 Clinical efficacy and safety of abatacept in methotrexate-naive patients with early

rheumatoid arthritis and poor prognostic factors R Westhovens, M Robles, A C Ximenes, S Naviager, J Wollenhaupt, P Durez, J Gomez-Reino, W Grassi, B Haraoui, W Shergy, S-H Park, H Genant, C Peterfy, J-C Becker, A Covucci, R Helfrick, J Bathon

1878 Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of

A-L Hachulla, D Launay, V Gaxotte, P de Groote, N Lamblin, P Devos, P-Y Hatron, J-P Beregi, E Hachulla

1885 N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment?

Y Allanore, K Wahbi, D Borderie, S Weber, A Kahan,

1890 Natural course of knee osteoarthritis in middleaged subjects with knee pain: 12-year follow-up using clinical and radiographic criteria C A Thorstensson, M L E Andersson, H Jönsson, T Saxne, I F Petersson

1894 Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients M C Genovese, F C Breedveld, P Emery, S Cohen, E Keystone, E L Matteson, Y Baptiste, A Chai, L Burke, W Reiss, M Sweetser, T M Shaw

MORE CONTENTS ▶



This article has been chosen by the editor to be of special interest or importance and is freely available online.





This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk





1898 Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, doubleblind, placebo-controlled study

G Haugeberg, P G Conaghan, M Quinn, P Emery

Basic and translational research

1902 Effects of *Porphyromonas gingivalis* on cell cycle progression and apoptosis of primary human chondrocytes

N Pischon, E Röhner, A Hocke, P N'Guessan, H C Müller, G Matziolis, V Kanitz, P Purucker, B-M Kleber, J-P Bernimoulin, G Burmester, F Buttgereit, J Detert

1908 FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment

S Raghavan, D Cao, M Widhe, K Roth, J Herrath, M Engström, G Roncador, A H Banham, C Trollmo, A I Catrina, V Malmström

1916 Association of the *DVWA* and *GDF5* polymorphisms with osteoarthritis in UK populations

A M Valdes, T D Spector, S Doherty, M Wheeler, D I Hart, M Doherty

1921 Association study of a polymorphism of the *CTGF* gene and susceptibility to systemic sclerosis in the Japanese population

Y Kawaguchi, Y Ota, M Kawamoto, I Ito, N Tsuchiya, T Sugiura, Y Katsumata, M Soejima, S Sato, M Hasegawa, M Fujimoto, K Takehara, M Kuwana, H Yamanaka, M Hara

1925 Definition of arthritis candidate risk genes by combining rat linkage-mapping results with human case-control association data

L Bäckdahl, J P Guo, M Jagodic, K Becanovic,
B Ding, T Olsson, J C Lorentzen

Letters

1933 Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis

U Rauchhaus, R W Kinne, D Pohlers, S Wiegand, A Wölfert, M Gajda, R Bräuer, S Panzner

1934 Anti-tumour necrosis factor α therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment

> L Naumann, D Huscher, J Detert, M Spengler, G-R Burmester, F Buttgereit

